Dr. Deodhar has received consultancies and speaking fees (less than $10,000 each) from Centocor, Genentech, and Takeda.
Contribution from the Field
Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients†
Version of Record online: 30 MAR 2010
Copyright © 2010 by the American College of Rheumatology
Arthritis Care & Research
Volume 62, Issue 4, pages 569–574, April 2010
How to Cite
Deodhar, A., Dore, R. K., Mandel, D., Schechtman, J., Shergy, W., Trapp, R., Ory, P. A., Peterfy, C. G., Fuerst, T., Wang, H., Zhou, L., Tsuji, W. and Newmark, R. (2010), Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res, 62: 569–574. doi: 10.1002/acr.20004
ClinicalTrials.gov identifier: NCT00095498.
- Issue online: 30 MAR 2010
- Version of Record online: 30 MAR 2010
- Manuscript Accepted: 11 DEC 2009
- Manuscript Received: 15 JUN 2009
- Amgen Inc.
- 10Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2009; 68: 1898–901., , , .
- 13Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58: 1299–309., , , , , , et al.